Exploring Three High Growth Tech Stocks In The United States

In This Article:

In the last week, the United States market has been flat, yet it has seen a 20% increase over the past year with earnings projected to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks that align with these promising market conditions can be crucial for investors seeking opportunities in this dynamic sector.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

24.36%

24.28%

★★★★★★

Ardelyx

21.09%

55.29%

★★★★★★

AVITA Medical

33.20%

51.87%

★★★★★★

Alnylam Pharmaceuticals

21.62%

56.70%

★★★★★★

TG Therapeutics

29.48%

43.58%

★★★★★★

Alkami Technology

21.99%

102.65%

★★★★★★

Travere Therapeutics

30.52%

61.89%

★★★★★★

Clene

61.16%

59.11%

★★★★★★

Blueprint Medicines

23.52%

55.74%

★★★★★★

Lumentum Holdings

21.25%

118.58%

★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

BioCryst Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BioCryst Pharmaceuticals, Inc. is a biotechnology company that focuses on developing oral small-molecule and protein therapeutics for rare diseases, with a market cap of $1.81 billion.

Operations: BioCryst Pharmaceuticals generates revenue primarily from its biotechnology segment, specifically focusing on startups, with reported revenues of $412.58 million. The company is involved in the development of therapeutics for rare diseases.

BioCryst Pharmaceuticals, despite being unprofitable, is navigating a promising trajectory with an anticipated shift to profitability within three years. The company's recent guidance reveals a robust revenue uptick, projecting $540 million to $560 million for 2025, underpinned by a 36% year-on-year growth in 2024. This performance is bolstered by strategic product expansions like ORLADEYO, the first oral treatment for hereditary angioedema—now approved in 44 countries—which not only diversifies its portfolio but also enhances its market presence significantly.

NasdaqGS:BCRX Earnings and Revenue Growth as at Feb 2025
NasdaqGS:BCRX Earnings and Revenue Growth as at Feb 2025

Roku

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market capitalization of approximately $12.34 billion.

Operations: Roku generates revenue primarily through its Platform segment, which includes advertising and content distribution, contributing $3.32 billion. The Devices segment, encompassing the sale of streaming players and audio products, adds $580 million to the total revenue.